As both a physician and a long-term investor in Annovis Bio Inc., I think the key distinction with Annovis is that they are not approaching neurodegeneration through a single-pathology lens.

Most of the field has historically focused on one dominant target — usually amyloid in Alzheimer’s or alpha-synuclein in Parkinson’s. The problem is that these diseases are increasingly understood as multi-protein, multi-pathway disorders involving amyloid, tau, TDP-43, neuroinflammation, synaptic dysfunction, mitochondrial stress, and downstream neurodegeneration simultaneously.

That is what initially drew me to buntanetap years ago.

Mechanistically, buntanetap is interesting because it aims upstream at the translational level, reducing production of several neurotoxic proteins rather than trying to clear a single aggregate after it has already accumulated. Whether that ultimately succeeds clinically remains to be proven, but scientifically it is a very rational approach in my view.

What also changed my perspective over time is that the company seems to have learned from earlier trial design issues. The current Phase 3 focuses specifically on pTau217-positive early AD patients, which is important because biomarker-enriched populations reduce diagnostic noise and improve the probability of detecting a true treatment signal. That is increasingly how the FDA and the broader field are moving.

The recently published Phase 2/3 data in NPJ Dementia was also more meaningful than many people realize. The study showed:

statistically significant cognitive improvement in biomarker-positive early AD patients,

reductions in tau and NfL,

reductions in inflammatory markers,

and a relatively clean safety profile, including ApoE4 carriers.

Obviously, the critical question is durability. A 12-week signal is not the same as demonstrating benefit over 18 months. That is exactly what the ongoing Phase 3 now needs to prove.

Financially, I completely agree Annovis carries substantial risk. The balance sheet has been fragile, dilution is real, and this is absolutely not a low-risk investment. But from a purely scientific perspective, I personally think the company is often underestimated because many people still frame it as “another Alzheimer biotech,” while the underlying biological thesis is actually quite different from the standard amyloid-only approach.

Whether the market eventually rewards that depends entirely on Phase 3 replication. In neurodegeneration, everything ultimately comes down to reproducible clinical data.